primary scleroding cholangitis. K80-K87
Conditions
Interventions
Intervention 1: Intervention group: UDCA drug dose of 300 mg daily 8 to 10 mg per kilogram of body weight divided into two to three doses by So.Se.Pharm plus fenofibrate dose of 200 mg b.i.d for 12 we
Sponsors
Rasht University of Medical Sciences
Eligibility
Sex/Gender
All
Age
20 Years to 70 Years
Inclusion criteria
Inclusion criteria: Patients with PSC disease confirmed by a specialist using ERCP or MRCP.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary scleroding cholangitis treatment. Timepoint: Before starting treatment, weeks 6, 12,18,24,30,36 from the point of view ALT, AST, ALP, Gamma- Glutamyl transpeptidase, Bilirubin Total, Bilirubin Direct,Albumin and Prothrombin and weeks 12,24,36 from the point of view TG, Total-Cholesetrol and LDL. Method of measurement: Blood test. | — |
Secondary
| Measure | Time frame |
|---|---|
| Response to treatment and possible side effect. Timepoint: Weeks 6, 12,18,24,30,36 from the point of view ALT, AST, ALP,Gamma-Glutamyl transpeptidase,Bilirubin Total,Bilirubin Direct,Albumin and Protrombin and weeks 12,24,36 from the point of view TG, Total-Cholestrol and LDL. Method of measurement: Blood test. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public Contact???? ?????? ?????
Rasht University of Medical Sciences
Outcome results
None listed